Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Progesterone Receptor Positive Tumor: early-phase trial registry
A small indexed set (2 trials) with no open enrollment listed right now.
Corpus placement: #7,188 of 28,707 conditions by registered trial count.
2 US clinical trials · none currently recruiting · #7,188 of 28,707 conditions by registered trial count
Progesterone Receptor Positive Tumor: 2 US clinical trials tracked, none currently recruiting.
Progesterone Receptor Positive Tumor is the subject of 2 registered US clinical trials on ClinicalTrials.gov, none currently recruiting. 0 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is University of Arizona, running 1 of these trials.
Enrollment posture brief
Registry condition progesterone-receptor-positive-tumor
OPEN 0 | RECR 0% | LATE 0 | EARLY 1 | RANK #7188 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Accelerated Phase Chronic Myelogenous Leukemia (0% recruiting · 12 trials)
Progesterone Receptor Positive Tumor has no open enrollment in this registry pull (2 archived studies). Peers show how other volume-matched labels compare on open share. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Progesterone Receptor Positive Tumor on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Progesterone Receptor Positive Tumor is recruiting below its size-band peers.
0 of 2 indexed trials (0%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Indexed trials (enrollment closed)
2 total, page 1 of 1
Neoadjuvant Pembrolizumab + Decitabine Followed by Std Neoadj Chemo for Locally Advanced HER2- Breast Ca
Virginia Commonwealth University
NCT02957968
Pilot Study Estradiol Followed by Exemestane Hormone Receptor + Metastatic Breast Cancer
University of Arizona
NCT01385280
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Progesterone Receptor Positive Tumor records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Progesterone Receptor Positive Tumor trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Progesterone Receptor Positive Tumor page
2 registered trials, 0 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- No Progesterone Receptor Positive Tumor trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- University of Arizona sponsors the most Progesterone Receptor Positive Tumor trials on record, review their full trial history before evaluating a specific study. See University of Arizona's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Progesterone Receptor Positive Tumor condition card totals 2 registered trials; most-linked intervention enzyme-linked immunosorbent assay; top US site state Virginia. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.